Cargando…

Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer

BACKGROUND/AIMS: The benefit of second-line chemotherapy (SL) after failed first-line chemotherapy (FL) in patients with advanced pancreatic cancer has not yet been established. We evaluated the clinical characteristics affecting the benefits of SL compared to best supportive care (BSC), identified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jeung Eun, Lee, Hee Seung, Chung, Moon Jae, Park, Jeong Youp, Park, Seung Woo, Song, Si Young, Bang, Seungmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974334/ https://www.ncbi.nlm.nih.gov/pubmed/30974927 http://dx.doi.org/10.5009/gnl18419

Ejemplares similares

Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer
por: Moon, Do Chang, et al.
Publicado: (2016)

Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
por: Park, Semi, et al.
Publicado: (2013)

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)

Clinical characteristics of second primary pancreatic cancer
por: Jo, Jung Hyun, et al.
Publicado: (2017)

Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2019)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

Establishment of pancreatic cancer cell lines with endoscopic ultrasound‐guided biopsy via conditionally reprogrammed cell culture
por: Lee, Hee Seung, et al.
Publicado: (2019)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer
por: Kang, Huapyong, et al.
Publicado: (2018)

Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer
por: Chung, Joo Won, et al.
Publicado: (2017)

Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer
por: Lee, Hee Seung, et al.
Publicado: (2021)

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
por: Park, Chan Su, et al.
Publicado: (2022)

Statin Use and Its Impact on Survival in Pancreatic Cancer Patients
por: Lee, Hee Seung, et al.
Publicado: (2016)

Urgent endoscopic retrograde cholangiopancreatography is not superior to early ERCP in acute biliary pancreatitis with biliary obstruction without cholangitis
por: Lee, Hee Seung, et al.
Publicado: (2018)

Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study
por: Keum, Jiyoung, et al.
Publicado: (2022)

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
por: Lee, Sang Hoon, et al.
Publicado: (2020)

Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective study
por: Lee, Hee Seung, et al.
Publicado: (2023)

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
por: Lee, Kyoungmin, et al.
Publicado: (2020)

Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
por: Huh, Gunn, et al.
Publicado: (2021)

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
por: Chung, Moon Jae, et al.
Publicado: (2018)

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
por: Park, Ji Hoon, et al.
Publicado: (2022)

Clinical Value of Contrast-Enhanced Harmonic Endoscopic Ultrasonography in the Differential Diagnosis of Pancreatic and Gallbladder Masses
por: Leem, Galam, et al.
Publicado: (2018)

Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer
por: Kang, Huapyong, et al.
Publicado: (2022)

Long-term outcomes of fully covered self-expandable metal stents versus plastic stents in chronic pancreatitis
por: Lee, Sang Hoon, et al.
Publicado: (2021)

Bleeding Complications and Clinical Safety of Endoscopic Retrograde Cholangiopancreatography in Patients with Liver Cirrhosis
por: Kim, Ji Yeon, et al.
Publicado: (2019)

Gastrointestinal Hemorrhage after Concurrent Chemoradiotherapy in Locally Advanced Pancreatic Cancer
por: Lee, Kyong Joo, et al.
Publicado: (2013)

A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer
por: Lee, Kyong Joo, et al.
Publicado: (2016)

Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial
por: Keum, Jiyoung, et al.
Publicado: (2021)

A novel lumen-apposing metal stent with an anti-reflux valve for endoscopic ultrasound-guided drainage of pseudocysts and walled-off necrosis: A pilot study
por: Cho, In Rae, et al.
Publicado: (2019)

Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis
por: Oh, Tak Geun, et al.
Publicado: (2014)

Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial
por: Leem, Galam, et al.
Publicado: (2022)

Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer
por: Lee, Hee Seung, et al.
Publicado: (2018)

Impact of cholecystectomy on acute coronary syndrome according to metabolic condition: a nationwide population-based cohort study
por: Chae, Wonjeong, et al.
Publicado: (2023)

Systemic Chemotherapy in Advanced Pancreatic Cancer
por: Lee, Hee Seung, et al.
Publicado: (2016)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
por: Yoon, Min Sung, et al.
Publicado: (2022)

Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma
por: Jung, Jang Han, et al.
Publicado: (2017)

First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
por: Han, Sung Yong, et al.
Publicado: (2020)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Radiotherapy Prolongs Biliary Metal Stent Patency in Malignant Pancreatobiliary Obstructions
por: Park, Semi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_oqr8k92bqvbuvnr82pqg05necp